Anaesthesia for renal transplant surgery

Renal transplantation is the preferred therapeutic option for patients with end‐stage renal disease. Survival rates are much higher in patients who receive a transplant. Patients with renal failure have significant concomitant medical conditions, such as cardiovascular disease. This article provides an overview of the important issues to be considered in patients undergoing renal transplant, and discusses the anaesthetic management of these patients.

[1]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[2]  F. Marumo,et al.  Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. , 2000, Journal of the American Society of Nephrology : JASN.

[3]  P. Prokocimer,et al.  Inhalation Toxicity Study of a Haloalkene Degradant of Sevoflurane, Compound A (PIFE), in Sprague‐Dawley Rats , 1995, Anesthesiology.

[4]  T. Loop,et al.  Sevoflurane Inhibits Phorbol-Myristate-Acetate-induced Activator Protein-1 Activation in Human T Lymphocytes in Vitro: Potential Role of the p38-Stress Kinase Pathway , 2004, Anesthesiology.

[5]  R. Strauss,et al.  An international view of hydroxyethyl starches , 1999, Intensive Care Medicine.

[6]  R. Heyka,et al.  Lipoprotein(a) Is an Independent Risk Factor for Cardiovascular Disease in Hemodialysis Patients , 1992, Circulation.

[7]  M. Tonelli,et al.  NSAID use and progression of chronic kidney disease. , 2007, The American journal of medicine.

[8]  K. Ikeda,et al.  Effects of Low‐flow Sevoflurane Anesthesia on Renal Function: Comparison with High‐flow Sevoflurane Anesthesia and Low‐flow Isoflurane Anesthesia , 1997, Anesthesiology.

[9]  A. Moustapha,et al.  Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. , 1998, Circulation.

[10]  G. London,et al.  Hyperphosphataemia--a silent killer of patients with renal failure? , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  Ronald D. Miller,et al.  The Pharmacodynamics and Pharmacokinetics of Vecuronium in Patients Anesthetized with Isoflurane with Normal Renal Function or with Renal Failure , 1988, Anesthesiology.

[12]  M. Kirvela,et al.  The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation. , 1996, Journal of clinical anesthesia.

[13]  J. Hunter.  Muscle relaxants in renal disease * , 1994, Acta anaesthesiologica Scandinavica. Supplementum.

[14]  R. Thisted,et al.  Association of Preoperative Risk Factors with Postoperative Acute Renal Failure , 1994, Anesthesia and analgesia.

[15]  U. Finsterer,et al.  Rapid saline infusion produces hyperchloremic acidosis in patients undergoing gynecologic surgery. , 1999, Anesthesiology.

[16]  D. Manninen,et al.  The center effect in kidney transplantation. , 1991, Transplantation proceedings.

[17]  G. London,et al.  Cardiac disease in chronic uremia: pathogenesis. , 1997, Advances in renal replacement therapy.

[18]  S. Iwarson.  The natural course of chronic hepatitis C. , 1994, FEMS microbiology reviews.

[19]  G. Russell,et al.  Dialysis modality and delayed graft function after cadaveric renal transplantation. , 1999, Journal of the American Society of Nephrology : JASN.

[20]  G. Park,et al.  Effect of renal failure on drug metabolism by the liver. , 1993, British journal of anaesthesia.

[21]  S. Bhagani,et al.  Guidelines for kidney transplantation in patients with HIV disease * , 2006, HIV medicine.

[22]  P. Andrews,et al.  Management of the diabetic patient approaching end-stage renal failure: , 2002 .

[23]  S. Hariharan,et al.  Improved graft survival after renal transplantation in the United States, 1988 to 1996. , 2000, The New England journal of medicine.

[24]  A. Levey.  Controlling the epidemic of cardiovascular disease in chronic renal disease: where do we start? , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[25]  P. Kimmel,et al.  Immunologic function and survival in hemodialysis patients. , 1998, Kidney international.

[26]  S. Yusuf,et al.  Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53. , 2000 .

[27]  A. Levey,et al.  THE IMPACT OF PRETRANSPLANTATION HEPATITIS C INFECTION ON THE OUTCOME OF RENAL TRANSPLANTATION , 1995, Transplantation.

[28]  H. Renck.  Wound infiltration with local anaesthetics , 1994, Acta anaesthesiologica Scandinavica.

[29]  B. Kasiske,et al.  The evaluation of candidates for renal transplantation. The current practice of U.S. transplant centers. , 1994, Transplantation.

[30]  P. Coriat,et al.  Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients , 1996, The Lancet.

[31]  C. Visser,et al.  C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? , 1999, Circulation.

[32]  F. Cosio,et al.  Patient survival after renal transplantation: I. The impact of dialysis pre-transplant. , 1998, Kidney international.

[33]  D. Churchill,et al.  Comparison of mortality risk for dialysis patients and cadaveric first renal transplant recipients in Ontario, Canada. , 2000, Journal of the American Society of Nephrology : JASN.

[34]  R. Foley,et al.  Clinical epidemiology of cardiovascular disease in chronic renal disease. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[35]  M. Kessler,et al.  Relationship between blood pressure and renin, angiotensin II and atrial natriuretic factor after renal transplantation. , 1997, Clinical nephrology.

[36]  R. Gibey,et al.  Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: a prospective study. , 2000, Journal of the American Society of Nephrology : JASN.

[37]  A. Yli-Hankala,et al.  Comparison of propofol/alfentanil anaesthesia with isoflurane/N2O/fentanyl anaesthesia for renal transplantation , 1994, Acta anaesthesiologica Scandinavica.

[38]  A. Vandesteene,et al.  Propofol infusion for induction and maintenance of anaesthesia in patients with end-stage renal disease. , 1998, British journal of anaesthesia.

[39]  P. Ureña,et al.  [Incidence and development of aortic stenosis in chronic hemodialysis. An ultrasonographic and biological study of 112 patients]. , 1997, Archives des maladies du coeur et des vaisseaux.

[40]  S. Joel,et al.  The pharmacokinetics of morphine and morphine glucuronides in kidney failure , 1993, Clinical pharmacology and therapeutics.

[41]  J. Daurès,et al.  Pharmacodynamics of vecuronium in patients with and without renal failure: a meta-analysis , 1993, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[42]  M. Bedel,et al.  The effect of intravenous lactated Ringer's solution versus 0.9% sodium chloride solution on serum osmolality in human volunteers. , 1999, Anesthesia and analgesia.

[43]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[44]  M. K. James,et al.  Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. , 1997, The Journal of pharmacology and experimental therapeutics.

[45]  W. Schlack,et al.  Post-conditioning by a short administration of desflurane reduced renal reperfusion injury after differing of ischaemia times in rats. , 2006, British journal of anaesthesia.

[46]  C. Pouteil‐Noble,et al.  Glomerular disease associated with hepatitis C virus infection in native kidneys. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[47]  J. Briggs,et al.  RENAL TRANSPLANTATION IN THE UNITED KINGDOM AND IRELAND—THE CENTRE EFFECT , 1985, The Lancet.

[48]  J. T. Marsh,et al.  rHuEPO treatment improves brain and cognitive function of anemic dialysis patients. , 1991, Kidney international.

[49]  M. Pfeffer,et al.  Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[50]  Francesco Locatelli,et al.  Effect of dialysis dose and membrane flux in maintenance hemodialysis. , 2003, The New England journal of medicine.

[51]  S. Rostand.  Coronary heart disease in chronic renal insufficiency: some management considerations. , 2000, Journal of the American Society of Nephrology : JASN.

[52]  J. Hunter,et al.  Use of mivacurium chloride by constant infusion in the anephric patient. , 1992, British journal of anaesthesia.

[53]  J. Walls,et al.  End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link? , 2001, Kidney international.

[54]  L. Lindgren,et al.  Are diabetic patients in danger at renal transplantation? An invasive perioperative study , 2000, European journal of anaesthesiology.

[55]  J. Sear,et al.  Disposition of alfentanil in patients receiving a renal transplant , 1989, The Journal of pharmacy and pharmacology.

[56]  S. Yentis.  Suxamethonium and Hyperkalaemia , 1990, Anaesthesia and intensive care.

[57]  A. Kausz,et al.  Anemia: A Continuing Problem Following Kidney Transplantation , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[58]  E. Kang,et al.  Reversible Sequestration of Nitric Oxide by Hemoglobin During Hemodialysis in End-Stage Renal Disease , 2001, The American journal of the medical sciences.

[59]  M. R. Mickey,et al.  COMPARISON OF KIDNEY TRANSPLANT SURVIVAL AMONG TRANSPLANT CENTERS , 1975, Transplantation.

[60]  L. Ratner,et al.  Early hemodynamic changes after renal transplantation: determinants of low central venous pressure in the recipients and correlation with acute renal dysfunction. , 2003, Medical science monitor : international medical journal of experimental and clinical research.

[61]  B. Zingman,et al.  Long-term survival in an HIV-infected renal transplant recipient. , 1997, American journal of nephrology.

[62]  C. Wanner,et al.  Cardiovascular disease determinants in chronic renal failure: clinical approach and treatment. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[63]  J. Hunter,et al.  Disposition of infusions of atracurium and its metabolite, laudanosine, in patients in renal and respiratory failure in an ITU. , 1988, British journal of anaesthesia.

[64]  R. Purcell,et al.  Interrelationship of blood transfusion, non‐A, non‐B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus , 1990, Hepatology.

[65]  F. González-Roncero,et al.  Outcome of kidney transplant in chronic hepatitis C virus patients: effect of pretransplantation interferon-alpha2b monotherapy. , 2003, Transplantation proceedings.

[66]  P. Rehak,et al.  Total intravenous anesthesia with remifentanil, propofol and cisatracurium in end-stage renal failure , 1999, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[67]  F. Donati,et al.  Vecuronium in renal failure , 1984, Canadian Anaesthetists' Society journal.

[68]  A. Ojo,et al.  Hepatitis C antibody status and outcomes in renal transplant recipients. , 2001, Transplantation.

[69]  B. Charra,et al.  Importance of treatment time and blood pressure control in achieving long-term survival on dialysis. , 1996, American journal of nephrology.

[70]  P. Schnuelle,et al.  Perioperative fluid management in renal transplantation: a narrative review of the literature , 2006, Transplant international : official journal of the European Society for Organ Transplantation.

[71]  H. Szeto,et al.  Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure of cancer. , 1977, Annals of internal medicine.

[72]  P. Glass,et al.  Pharmacokinetics Anesthesiologists, and Pharmacodynamics of Remifentanil in Persons with Renal Failure Compared with Healthy Volunteers , 1997 .

[73]  K. Ikeda,et al.  Effect of total flow rate on the concentration of degradation products generated by reaction between sevoflurane and soda lime. , 1995, British Journal of Anaesthesia.

[74]  R. Lang,et al.  Cardiovascular consequences of correction of the anemia of renal failure with erythropoietin. , 1993, Kidney international.

[75]  M. Fisher,et al.  Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease. , 2005, Journal of the American College of Cardiology.

[76]  J. Puschett,et al.  Evaluation of cardiovascular risk for renal transplantation in diabetic patients. , 1987, The American journal of medicine.

[77]  R. Foley,et al.  Left ventricular hypertrophy in the renal patient. , 2001, Journal of the American Society of Nephrology : JASN.

[78]  H. Thomsen,et al.  Influence of normal central venous pressure on onset of function in renal allografts. , 1987, Scandinavian journal of urology and nephrology.

[79]  K. Leunissen,et al.  Short- and long-term results with adult non-heart-beating donor kidneys. , 1988, Transplantation proceedings.

[80]  A. Guérin,et al.  Calcification of the aortic valve in the dialyzed patient. , 2000, Journal of the American Society of Nephrology : JASN.

[81]  Hristopher,et al.  IMPROVED GRAFT SURVIVAL AFTER RENAL TRANSPLANTATION IN THE UNITED STATES , 1988 TO 1996 , 2022 .

[82]  K. Eckardt,et al.  Cardiovascular consequences of renal anaemia and erythropoietin therapy. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[83]  J. Hunter,et al.  Pharmacokinetics and pharmacodynamics of the three isomers of mivacurium in health, in end-stage renal failure and in patients with impaired renal function. , 1995, British journal of anaesthesia.

[84]  R. Miller,et al.  The Pharmacokinetics and Pharmacodynamics of Atracurium in Patients with and without Renal Failure , 1984, Anesthesiology.

[85]  M. Hübler,et al.  Renal Responses to Desflurane and Isoflurane in Patients with Renal Insufficiency , 2002, Anesthesiology.

[86]  D. Prough,et al.  Acidosis associated with perioperative saline administration: dilution or delusion? , 2000, Anesthesiology.

[87]  D. Le Guludec,et al.  Diagnostic accuracy and prognostic value of combined dipyridamole-exercise thallium imaging in hemodialysis patients. , 1998, Kidney international.

[88]  K. Khuenl-Brady,et al.  The use of rocuronium (ORG 9426) in patients with chronic renal failure , 1993, Anaesthesia.

[89]  J. Grady,et al.  Highly active antiretroviral therapy improves survival of HIV-infected hemodialysis patients. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[90]  Eld,et al.  COMPARISON OF MORTALITY IN ALL PATIENTS ON DIALYSIS , PATIENTS ON DIALYSIS AWAITING TRANSPLANTATION , AND RECIPIENTS OF A FIRST CADAVERIC TRANSPLANT , 2000 .

[91]  R. Foley,et al.  Cardiac function and hematocrit level. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[92]  G. Opelz,et al.  Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. , 1998, Kidney international.

[93]  C. Zoccali,et al.  Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study , 2001, The Lancet.

[94]  J. Kellum.  Determinants of blood pH in health and disease , 2000, Critical care.

[95]  David C. Murray,et al.  Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. , 1996, Kidney international.

[96]  E. Eger,et al.  Toxicity of Compound A in Rats: Effect of a 3‐Hour Administration , 1994, Anesthesiology.

[97]  N. Nathan,et al.  Pharmacokinetics of propofol and its conjugates after continuous infusion in normal and in renal failure patients: a preliminary study. , 1993, Acta anaesthesiologica Belgica.

[98]  M. Bahner,et al.  Advanced Coronary and Carotid Arteriopathy in Young Adults With Childhood-Onset Chronic Renal Failure , 2002, Circulation.

[99]  David C. Murray,et al.  Outcome and risk factors for left ventricular disorders in chronic uraemia. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[100]  Pharmacokinetics of mivacurium in normal patients and in those with hepatic or renal failure. , 1992, British journal of anaesthesia.

[101]  J. Ma,et al.  Chronic viral hepatitis enhances the risk of infection but not acute rejection in renal transplant recipients. , 1996, Transplantation.

[102]  A. Yli-Hankala,et al.  Pharmacokinetics of propofol and haemodynamic changes during induction of anaesthesia in uraemic patients. , 1992, British journal of anaesthesia.

[103]  J. Hunter,et al.  Comparison of vecuronium, atracurium and tubocurarine in normal patients and in patients with no renal function. , 1984, British journal of anaesthesia.

[104]  J. Wierda,et al.  Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. , 1993, British journal of anaesthesia.

[105]  M. Pinaud,et al.  Vecuronium and atracurium in patients with end-stage renal failure. A comparative study. , 1987, British journal of anaesthesia.

[106]  S. Nasr,et al.  Differential Protective Effects of Volatile Anesthetics against Renal Ischemia–Reperfusion Injury In Vivo , 2004, Anesthesiology.

[107]  R. Elashoff,et al.  Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. , 2000, The New England journal of medicine.

[108]  R. Merion,et al.  Usefulness of dobutamine stress echocardiography in detecting coronary artery disease in end-stage renal disease. , 1995, The American journal of cardiology.

[109]  R. Brunkhorst,et al.  Hypertension as a possible complication of recombinant human erythropoietin therapy. , 1991, Contributions to nephrology.

[110]  M. Reidenberg.  The biotransformation of drugs in renal failure. , 1977, The American journal of medicine.

[111]  A. Schwarz,et al.  Nephrotoxicity of selective COX-2 inhibitors. , 2001, The Journal of rheumatology.

[112]  W. Mauritz,et al.  [Protracted action of vecuronium in a patient with chronic renal insufficiency treated by dialysis]. , 1988, Der Anaesthesist.

[113]  J. Squifflet,et al.  MAXIMAL HYDRATION DURING ANESTHESIA INCREASES PULMONARY ARTERIAL PRESSURES AND IMPROVES EARLY FUNCTION OF HUMAN RENAL TRANSPLANTS , 1982, Transplantation.

[114]  R. Frumento,et al.  A Randomized, Double-Blind Comparison of Lactated Ringer’s Solution and 0.9% NaCl During Renal Transplantation , 2005, Anesthesia and analgesia.

[115]  C. Alexander,et al.  End-stage renal disease-associated managed care costs among patients with and without diabetes. , 2004, Diabetes care.

[116]  J. Farman,et al.  Suxamethonium hyperkalaemia in uraemic neuropathy , 1973, Anaesthesia.

[117]  M. Olschewski,et al.  Impact of hepatitis B and C on graft loss and mortality of patients after kidney transplantation , 2002, Clinical transplantation.

[118]  R. Wolfe,et al.  Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. , 1993, JAMA.

[119]  I. Davidson.  Renal impact of fluid management with colloids: a comparative review , 2006, European journal of anaesthesiology.

[120]  C. Stehman-Breen,et al.  Risk of death among chronic dialysis patients infected with hepatitis C virus. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[121]  P. Kuo,et al.  Extending the boundaries of acceptable organ donors: a means of expanding the donor pool for liver transplantation. , 1997, Transplantation proceedings.

[122]  John F. Hurdle,et al.  Duration of end-stage renal disease and kidney transplant outcome. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[123]  X. Zhuang,et al.  Selection of neuromuscular blocking agents in patients undergoing renal transplantation under general anesthesia. , 2002, Chinese medical journal.

[124]  J. Glen,et al.  Disposition and pharmacology of propofol glucuronide administered intravenously to animals. , 1992, Xenobiotica; the fate of foreign compounds in biological systems.

[125]  G. Kaysen,et al.  C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[126]  R. Wolfe,et al.  Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates. , 2001, Journal of the American Society of Nephrology : JASN.

[127]  R. Vanholder,et al.  Uraemic toxins and cardiovascular disease. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[128]  S. Rostand,et al.  The Management of Coronary Artery Disease in Patients with End-Stage Renal Disease , 1992 .

[129]  J. Weinberg.  The cell biology of ischemic renal injury. , 1991, Kidney international.

[130]  A. Sabato,et al.  Combined general and epidural anesthesia with ropivacaine for renal transplantation. , 2003, Minerva anestesiologica.

[131]  A. Artru,et al.  Low-flow sevoflurane compared with low-flow isoflurane anesthesia in patients with stable renal insufficiency. , 2002, Anesthesiology.

[132]  S. Bode-Böger,et al.  Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. , 1999, Journal of the American Society of Nephrology : JASN.

[133]  P. Ureña,et al.  Evolutive aortic stenosis in hemodialysis patients: analysis of risk factors. , 1999, Nephrologie.

[134]  S. Morgan,et al.  Renal Concentrating Function with Prolonged Sevoflurane or Enflurane Anesthesia in Volunteers , 1994, Anesthesiology.

[135]  P. Peeters,et al.  Hydroxyethyl starch does not impair immediate renal function in kidney transplant recipients: a retrospective, multicentre analysis. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[136]  L. Lindgren,et al.  Pharmacokinetics of glycopyrronium in uraemic patients. , 1993, British journal of anaesthesia.

[137]  P. Glass,et al.  Pharmacokinetics and pharmacodynamics of remifentanil in persons with renal failure compared with healthy volunteers. , 1998, Anesthesiology.

[138]  M. Gold,et al.  Desflurane Versus Isoflurane in Patients with Chronic Hepatic and Renal Disease , 1993, Anesthesia and analgesia.

[139]  G. London,et al.  Secondary hyperparathyroidism and cardiac hypertrophy in hemodialysis patients. , 1987, Kidney international.

[140]  E. Ritz,et al.  Myocyte/capillary mismatch in the heart of uremic patients. , 1998, Journal of the American Society of Nephrology : JASN.

[141]  K. Peter,et al.  Renal Function and Serum Fluoride Concentrations in Patients with Stable Renal Insufficiency After Anesthesia with Sevoflurane or Enflurane , 1995, Anesthesia and analgesia.

[142]  L. Prescott,et al.  Paracetamol disposition in renal allograft recipients , 2002, European Journal of Clinical Pharmacology.

[143]  A. DeBree,et al.  A Multicenter Study Evaluating the Effects of Sevoflurane on Renal Function in Patients With Renal Insufficiency , 1998, Journal of cardiovascular pharmacology and therapeutics.

[144]  D. Niakas,et al.  Overcoming inherent problems of preference-based techniques for measuring health benefits: An empirical study in the context of kidney transplantation , 2006, BMC Health Services Research.

[145]  G. Mayer,et al.  Working capacity is increased following recombinant human erythropoietin treatment. , 1988, Kidney international.

[146]  S. Morgan,et al.  Plasma Inorganic Fluoride With Sevoflurane Anesthesia: Correlation With Indices of Hepatic and Renal Function , 1992, Anesthesia and analgesia.